Clinical Trial Update: An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients [Phase 4]

View source ↗

Summary

Open-label Phase 4 study evaluating the safety, tolerability and clinical utility of ULTRACET for treatment of breakthrough pain in cancer patients; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ULTRACET (tramadol hydrochloride/acetaminophen)

Snippet

Sponsor: Johnson & Johnson Taiwan Ltd | Conditions: Pain | Phase 4 | Status: COMPLETED